Bi-or tri-specific T cell engagers (BiTE or TriTE) are recombinant bispecific proteins
designed to stimulate T-cell immunity directly, bypassing antigen presentation by antigen …

Bi-or tri-specific T cell engagers (BiTE or TriTE) are recombinant bispecific proteins
designed to stimulate T-cell immunity directly, bypassing antigen presentation by antigen …

Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that
redirect T cells to tumor surface antigens. While efficacious against certain hematological …

Oncolytic viruses (OVs) are potent anti-cancer biologics with a bright future, having
substantial evidence of efficacy in patients with cancer. Bi-and tri-specific antibodies …

Oncolytic viruses (OVs) are emerging as therapeutically relevant anticancer agents as
contemporary immunotherapy gains traction. Furthermore, OVs are an ideal platform for …

Tumor immunotherapy, especially T cell based therapy, is becoming the main force in
clinical tumor therapies. Bispecific T cell engager (BiTE) uses the single chain variable …

Oncolytic viruses (OVs) are novel anticancer agents that combine direct cancer cell killing
with the stimulation of antitumor immunity. In addition, OVs can be engineered to deliver …

Bispecific T‐cell engagers (BiTEs) are a new class of immunotherapeutic molecules
intended for the treatment of cancer. These molecules enhance the patient's immune …

Background Oncolytic virotherapy (OVT) is a promising anti-tumor modality that utilizes
oncolytic viruses (OVs) to preferentially attack cancers rather than normal tissues. With the …

Bispecific T cell engagers (BiTEs) that are specific for both a surface target antigen on
cancer cells and CD3 on T cells have been used to engage T cells for cancer therapies …